Home About this Site About Curtis Meinert About the CCT What's New

Good Practice Policies & Procedures (GPPP)

When you are up to your ass in alligators, it is hard to remember you started out to drain the swamp.  And so it was with this series.  It grew out of a written "dialog" with CLM on philosophical issues relating to the organization and operation of treatment effects monitoring committees.  A memo dated 26 April 2000 from CLM entitled Treatment effects monitoring in clinical trials caused me to set about writing, what I considered to be, good policies and practices for the Center in regard to treatment effects monitoring.  It gave rise to a related memo detailing, what I regarded, IRB good practice policies and procedures, and the series was born.

The series was produced over a period of 9 months starting with the distribution of the two memos mentioned above at mid year in 2001.  In all, a total of 40 memos were distributed as listed on the page above.  The dates on the memos themselves correspond to dates when the memos were born in some cases and in others when they were in nearly final form.

Once I had waded into the swamp of GPPPs for the Center, I realized the swamp was bigger than I had thought.  By the time I realized that I should have had a map marking the lily patches I wanted to visit, it was too late.  I had wandered too long map-less, so I just kept wandering until I ran out of lily patches I considered worth visiting.  No doubt, were I to be foolish enough to wade back into the swamp again without a map, the resulting series would be different.

I am, of course, aware that together the GPPPs are redundant and sometimes even contradictory – an inevitable result of wandering without a map.  I am aware, as well, that I have been cryptic and that many of the P&Ps could benefit from more narrative, but one gets tired of wading in mud.  No doubt, my tendency toward crypticism and terseness increased with time in the swamp.

I have profited from Barbara Martin's input in reading and commenting on some of the early GPPPs and from Susan Tonascia's steady and trusted hand.  Susan has read the majority of the GPPPs and provided comments, corrections, and additions.  Thank you Susan!

I must also thank Betty Collison (Watson to me).  She has had the job of distributing the GPPPs and keeping track of the resulting mess.  Thank you Betty!

1. Startup 21. Record retention and storage
2. Followup 22. Publication and presentation
3. Close-out 23. Ethics
4. Sample size 24. Notation and terminology
       
5. Forms design 25. Operations
6. Data collection 26. Public access
7. Data entry 27. Study e-mail
8. Data processing 28. Training, certification, quality control, & quality assurance
       
9. Analysis 29. Adverse event reporting
10. Screening and eligibility 30. Funding
11. Enrollment 31. Administration
12. Stratification 32. Organization
       
13. IRB 33. Meetings
14. Consent/assent 34. Conflict of interest disclosure and redress
15. Bias control 35. Drug labeling and distribution
16. Masking 36. Laboratory, reading, and banking
       
17. Variance reduction 37. Substudy, ancillary study, and auxiliary study
18. Randomization 38. Treatment effects monitoring
19. Randomization override 39. Treatment effects monitoring committee
20. Numbered memos 40. Generic
 

Last Updated:   24 Sep 2020

 

(Click here to get Adobe Acrobat Reader for free) getacro.gif (712 bytes)